Abstract 5483
Background
In epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC), there are various treatment challenges. Most patients develop resistance and relaps within 1-1.5 years after first-line EGFR- tyrosine kinase inhibitor (TKI) treatment [1st- and 2nd- generation (G) TKIs]. Some studies suggest that afatinib may overcome the tumor heterogeneity.
Methods
We conducted the multi-center retrospective study in patients with EGFR-mutant NSCLC after acquired resistance to EGFR-TKIs appeared at any line of therapy. The outcomes between afatinib followed by osimertinib and 1st-G EGFR TKIs followed by osimertinib (3rd-G EGFR TKI) were evaluated.
Results
We enrolled 111 T790M mutation-positive patients treated with osimertinib. The median age was 69 (range: 39-88) year old. Among them, 33 (29.7%) were male, 100 (90%) were with PS 0-1, and 35 (31.5%) were treated with afatinib followed by osimertinib. The median treatment line with afatinib or 1st-G EGFR TKI followed by osimertinib was 5 or 4. In all patients, the objective response and disease control rates were 63.1% and 77.5%, respectively. The objective response and disease control rates were significantly higher in patients with afatinib followed by osimertinib than in those with 1st-G EGFR TKI followed by osimertinib [82.9% vs 53.9% (p = 0.0065) and 91.4% vs 71.1% (p = 0.032)], respectively. The median PFS (with <60% events) was longer and in favor of afatinib followed by osimertinib compared with 1st-G EGFR TKI followed by osimertinib (15.7 vs 8.9 months, p = 0.195). The follow-up is still ongoing.
Conclusions
Afatinib followed by osimertinib may provide better clinical benefit for NSCLC patients harboring T790M mutation compared with 1st-G EGFR TKIs. Afatinib followed by osimertinib is one of the first line sequential options even if osimertinib can be used as a first line therapy.
Clinical trial identification
Legal entity responsible for the study
M. Tamiya.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract